October 6-14, 2018
40 participants, 23 women, 17 men from 14 countries
Faculty:
J. Ambler, Wockhardt Pharmaceuticals, USA; D. Andes, University of Wisconsin, USA; C. Arias, University of Texas, USA; D. Bikard, Institut Pasteur, France; S. Brisse, Institut Pasteur, France; E. Brown, McMaster University, Canada; K. Bush, Indiana University, USA; G. Challis, University of Warwick, UK; J.‑P. Charrier, bioMérieux, France; P. Courvalin, Institut Pasteur, France; J.‑D. Docquier, University of Siena, Italy; M. Doubovetzky, Sanofi, France; T. Dougherty, Harvard Medical School, USA; F. Fang, University of Washington USA; M. Fisher, St Georges University, UK; M. Gilmore, Harvard Medical School, USA; C. Grillot-Courvalin, Institut Pasteur, France; R. Hall, University of Sydney, AU; L. Hall-Stoodley, Ohio State University, USA; D. Hooper, Massachusetts General Hospital, USA; D. Hughes, Uppsala University, Sweden; S. Lahiri, Macrolide Pharmaceuticals, USA; F. Lebreton, Harvard Medical School, USA; M. Lipsitch, Harvard Medical School, USA; S. Lory, Harvard Medical School, USA; A. Mankin, University of Illinois, USA; H. Moser, Novartis, USA; A. Myers, Harvard University, USA; M. Page, Basel, Switzerland; K. Pos, Goethe University, Germany; S. Projan, MedImmune, USA; M. Pucci, Spero Therapeutics, USA; D. Rasko, University of Maryland, USA; G.-M. Rossolini, University of Siena, Italy; H.-G. Sahl, University of Bonn, Germany; M.-W. Tan, Genentech/Roche, USA; Y. Taur, Memorial Sloan Kettering Cancer Center, USA; J. Tomayko, Pfizer, USA; M. Trent, University of Georgia, USA; N. Vazquez-Laslop, University of Illinois, USA; T. Walsh, Cardiff University, UK; G. Wright, McMaster University, Canada
